The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The effect of a tamoxifen dose increase from 20 mg to 40 mg in patients with at least one inactive CYP2D6 variant allele and/or concomitant use of a CYP2D6 inhibitor.
M. E. B. Welzen
No relevant relationships to disclose
V. O. Dezentje
No relevant relationships to disclose
R. H. N. van Schaik
No relevant relationships to disclose
E. P. H. Colbers
No relevant relationships to disclose
H. Guchelaar
No relevant relationships to disclose
J. den Hartigh
No relevant relationships to disclose
D. M. Burger
No relevant relationships to disclose
H. Van Laarhoven
No relevant relationships to disclose